UNSPSC 51111606: Hydroxycarbamide or hydroxyurea

This classification denotes a ribonucleotide reductase inhibitor and miscellaneous antimetabolite with the molecular formula CH4N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X6Q56QN5QC, chemically known as urea, n-hydroxy- but generally known as hydroxycarbamide, which bears US NIH Compound Identifier 3657. European Medicines Agency schedules Hydroxycarbamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08076MIG.

UNSPSC 51111606 Hydroxycarbamide or hydroxyurea, a Commodity code, covers the procurement of this chemotherapy and hematologic agent by state and local health systems, correctional facilities, and safety-net providers. State and local governments purchase hydroxycarbamide primarily for treatment of sickle cell disease, certain cancers, and polycythemia vera within institutional pharmacy settings. The drug is sourced through state pharmacy benefit managers, group purchasing organizations, and direct vendor contracts negotiated at the state or health-system level. Buying entities include state departments of health, state correctional healthcare systems, county hospital systems, and municipally operated safety-net clinics.

The source provided contains no record of recent state or local solicitations under this code. Without posted RFP, RFQ, IFB, or ITB activity in the most-recent-opportunities dataset, no geographic concentration, issuing-body pattern, or representative recent opportunities can be identified. Procurement under this code typically occurs through routine pharmaceutical supply contracts and standing agreements rather than individual competitive procurements, which may account for the absence of posted competitive solicitation records.